Jiangsu Recbio Technology Co., Ltd. (Recbio) disclosed its Monthly Return for April 2026, detailing a large-scale conversion of onshore equity into Hong Kong-listed H shares.
Key Transaction • On 29 April 2026, 129.95 million Domestic Shares and 12.00 million Unlisted Foreign Shares were converted into 141.95 million H Shares. • No options, warrants or other equity instruments were involved.
Impact on Share Capital (par value: RMB 1.00) • Domestic Shares fell from 297.94 million to 167.98 million, a decrease of 129.95 million. • Unlisted Foreign Shares were fully eliminated, dropping from 12.00 million to zero. • H Shares rose from 316.14 million to 458.09 million, an increase of 141.95 million. • Total authorised and issued share capital now stands at 626.08 million shares, unchanged in aggregate but rebalanced toward the Hong Kong-listed class.
Public Float Recbio confirmed compliance with the Main Board’s minimum 25% public-float requirement following the conversion.
Regulatory Compliance The company stated that the share movements were duly authorised by the board and executed in accordance with Hong Kong Listing Rules and other applicable regulations.
The restructuring significantly enlarges Recbio’s tradable H-share base, aligning the share structure with its cross-border capital-market strategy while keeping overall share count steady.
Comments